Onyx’s Drug Gets Standard Review, Accelerated Approval in Question

Washington Drug Letter
A A
Onyx Pharmaceuticals’ multiple myeloma drug carfilzomib will receive a standard, 10-month, FDA review, another hurdle for the compound, which was expected to receive priority review.

To View This Article:

Login

Buy This Article Now

Add this article to your cart for $25.00